BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16452191)

  • 1. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components.
    Kubo T; Yamamoto H; Ichimura K; Jida M; Hayashi T; Otani H; Tsukuda K; Sano Y; Kiura K; Toyooka S
    Lung Cancer; 2009 Sep; 65(3):328-32. PubMed ID: 19144441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
    Pulling LC; Divine KK; Klinge DM; Gilliland FD; Kang T; Schwartz AG; Bocklage TJ; Belinsky SA
    Cancer Res; 2003 Aug; 63(16):4842-8. PubMed ID: 12941804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
    Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
    Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
    Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
    Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
    Nelson HH; Christiani DC; Wiencke JK; Mark EJ; Wain JC; Kelsey KT
    Cancer Res; 1999 Sep; 59(18):4570-3. PubMed ID: 10493509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program.
    Baryshnikova E; Destro A; Infante MV; Cavuto S; Cariboni U; Alloisio M; Ceresoli GL; Lutman R; Brambilla G; Chiesa G; Ravasi G; Roncalli M
    Clin Cancer Res; 2008 Mar; 14(6):1913-9. PubMed ID: 18347195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
    Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
    Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
    Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
    Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf.
    Wang Y; Zhang Z; Lubet R; You M
    Oncogene; 2005 Apr; 24(18):3042-9. PubMed ID: 15846305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
    van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
    Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
    Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA
    Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.